18264-Gall Bladder Cancer-NA-631

Gall Bladder Cancer

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number:

  • Address

6025 Lake Rd, Suite 110
Woodbury, MN 55125
P: (651) 735-7414

Search by practice name, trial titles, indicators and specific disease types.